Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy

A Pilot Project to Evaluate Feasibility and Patient Experience of Prehabilitation Care for Women With Advanced Ovarian Cancer Undergoing Neoadjuvant Chemotherapy

Status

Active, not recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04204811

Enrollment

Registered

2019-12-19

Start date

2019-12-16

Completion date

2026-12-16

Last updated

2026-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fallopian Tube Cancer, Fallopian Tube Carcinoma, Ovarian Cancer, Primary Peritoneal Carcinoma, Stage III Ovarian Cancer, Stage IV Ovarian Cancer

Keywords

Ovarian Cancer, Primary peritoneal carcinoma, Fallopian tube cancer, 19-347, Memorial Sloan Kettering Cancer Center

Brief summary

The purpose of this study is evaluate whether a prehabilitation program is feasible and useful for women with advanced ovarian cancer receiving chemotherapy in preparation for debulking surgery.

Interventions

OTHERPrehabilitation

A program of personalized independent home exercises are outline for participants to complete daily. Prehabilitation coaching will continue weekly until admission for surgical tumor debulking or termination of neoadjuvant treatment for any reason.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

SUPPORTIVE_CARE

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Subjects must be diagnosed with Stage III or Stage IV ovarian carcinoma (which includes primary peritoneal carcinoma or fallopian rube carcinoma) * All subjects must be enrolled within 90 days of diagnosis * No prior treatment for ovarian carcinoma * All subjects have agreed to a treatment plan of neoadjuvant chemotherapy and subsequent planned interval debulking surgery with an MSKCC surgeon * Participants must be initiating treatment at Gynecologic Medical Oncology clinics at MSKCC Manhattan * Proficiency in English in the determination of the investigators of by patient self-report

Exclusion criteria

* Patient under age 18 * Prior treatment for ovarian cancer * Second opinion visit only * Immediate surgery plan without neoadjuvant treatment * No intended surgical plan * Chemotherapy administration exclusively planned at MSKCC regional site * Patient unwilling to sign consent

Design outcomes

Primary

Measure	Time frame	Description
Median completion of participants	Up to 1 year	Study will be considered feasible if the cohort has a median completion of 70% or more

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026